AGP Executive Report
Last update: 12 hours agoUK Policy & Access: MHRA has approved an oral Wegovy tablet for weight management, expanding options beyond injections and potentially widening access for UK patients. Equity & Workforce: New research links overseas-born ethnic minority NHS staff to slower career progression, with migrant status not routinely captured in HR records. Stroke Tech & M&A: FDA clearance for Penumbra’s Thunderbolt clot-removal device is a boost for Boston Scientific as it moves to close the Penumbra acquisition. Primary Care Funding: Ghana’s Pusiga District Health Directorate launched a free primary healthcare policy, covering prevention, immunisation, maternal/child care, common illnesses, and referrals. Safety & Accountability: A UK inquest found system breakdown and staff failures led to the death of a patient mistakenly injected with insulin instead of local anaesthetic. Healthcare Costs & Regulation: Delaware’s Senate passed bills targeting medical debt protections and limits on private equity acquisitions of nonprofit hospitals, aiming to curb rising costs. Rare Disease Incentives: UK biotech urges MHRA’s rare disease therapy framework to go further, comparing it to the US FDA’s Priority Review Voucher incentives. Clinical Research: FDA priority review accepted for Roche’s atezolizumab-based adjuvant therapy in stage III dMMR/MSI-H colon cancer.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
.png?t=202606121858360)
